RESEARCH ARTICLE

Benzodiazepine prescription for patients in treatment for drug use disorders: a nationwide cohort study in Denmark, 2000–2010

Christian Tjagvad1*, Thomas Clausen1, Marte Handal2 and Svetlana Skurtveit1,2

Abstract

Background: Benzodiazepines are frequently prescribed to patients with drug use disorders. However, it has previously been difficult to distinguish whether this frequent prescribing was due to underlying psychiatric disorders or inappropriate prescribing. In a nationwide cohort study, we investigated the prescribing of benzodiazepines to patients with drug use disorders in connection with treatment admission.

Methods: Benzodiazepine prescriptions to patients (N = 33203) aged 18 to 67 years admitting for outpatient treatment for drug use disorders in Denmark, 2000 to 2010, were studied by using linked data from nationwide health registries. Factors associated with increasing amounts of benzodiazepine use within the first year after admission were assessed by multinomial logistic regression. Proportions of very long-term benzodiazepine prescription were calculated.

Results: During the first year after admission to treatment, 26.2 % of patients were prescribed benzodiazepines. Of these, 35.5 % were prescribed benzodiazepines at dose levels that might indicate inappropriate use (>365 Defined Daily Dose per year), and 34.6 % were prescribed more than one type of benzodiazepines. Diazepam was the most commonly prescribed type. Among patients with opioid use, 43.2 % were prescribed benzodiazepines which were three times higher than for patients with cannabis (12.2 %) or central stimulating drugs (13.8 %) as their primary drug use. Admitting to treatment for a drug use disorder did not increase the specialized psychiatric treatment coverage of this patient group, disregarding use of prescribed benzodiazepines. 29.5 % were new users of prescribed benzodiazepines, and of these, 27.5 % continued into very long-term use (≥4 years after admission) during the study period.

Conclusions: Benzodiazepines were commonly prescribed to patients admitting to treatment for drug use disorders, and included prescription of multiple and non-optimal types, high doses, and very long-term prescriptions. These findings point towards inappropriate prescribing of benzodiazepines in many cases more than treatment for psychiatric disorders.

Keywords: Benzodiazepines, Drug use disorders, Opioids, Cannabis, Central stimulating drugs, Long-term prescription, Addictive medication, Drug treatment, Cohort study, Denmark

* Correspondence: christian.tjagvad@medisin.uio.no
1Norwegian Centre for Addiction Research [SERAf], University of Oslo, Kirkeveien 166, Bygg 45, 0407 Oslo, Norway
Full list of author information is available at the end of the article

© 2016 The Author(s). Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
**Background**

Drug use disorders (DUDs) are common medical conditions and associated with significant morbidity and mortality [1]. Treatment of DUD reduces illicit drug use, morbidity, mortality, and crime [2–5]. In recent years, outpatient treatment of DUD has largely replaced previous traditions of inpatient treatment [6].

Benzodiazepines (BZDs) have long been used for conditions including various psychiatric disorders, insomnia, acute alcohol withdrawal, and epilepsy [7]. However, the use of BZDs has also been associated with a risk for dependence, abuse, and overdose death [8]. Patients with DUD use BZDs more frequently than the general population, including both legally prescribed and illicitly acquired BZDs [9]. Further, this patient group has both a higher prevalence of psychiatric disorders and an increased risk of developing a BZD abuse when using the medication [10–13]. Therefore, it has previously been difficult to distinguish whether the excess use of BZDs, particularly legally prescribed BZDs, among patients with DUD has been due to underlying psychiatric disorders or abuse; two conditions which require entirely different treatment regimes.

The prescribing of BZDs is mainly approved for short- to intermediate-term treatment in low doses. Benzodiazepines are not indicated for long-term use, except in the case of severe generalized anxiety disorder [14, 15]. In particular, long-term use among patients with DUD is of increasing concern, as it can result in cognitive impairment, difficulty in continuing treatment, tolerance, and dependence and abuse of BZDs [16–18]. Furthermore, the risk for adverse events, such as dependence and abuse, differs among the different types of BZDs. Certain types are preferred among drug using populations, and are often used in combination with other drugs [17, 19, 20]. BZDs used in combination with opioids may be particularly counterproductive in this patient group due to high risk of abuse [21]. Therefore, long-term prescriptions, high doses, less than optimal types of BZDs, and co-prescribing of opioids are all likely indicators of inappropriate prescribing of BZDs. On the other hand, initiation of psychiatric treatment for BZD users after admission to DUD treatment would be a likely indicator of an underlying psychiatric disorder. Investigation of such indicators among patients with DUD may help clarify whether the excess use of BZDs among this patient group is due to an underlying psychiatric disorders or inappropriate prescribing.

There are an estimated 33000 drug users in Denmark (latest numbers from 2009) with relatively stable treatment coverage of around 40 % during the last decades [6]. The outpatient treatment for patients with DUD is comprised of multiple service components, including acute detoxification, medication-assisted treatment, case management, and behavioral therapy. According to Danish guidelines, BZDs should not be prescribed to patients with DUD as a general rule [22]. Once admitted into treatment, guidelines state that DUD treatment should address the patient’s use of BZDs, and that BZDs should not be prescribed without coordinating within the overall treatment plan [22]. From 2000 to 2010, the prevalence of BZD use in the general Danish population decreased considerably, with an average one-year prevalence of 5-6 % during the entire period [23–25].

The Danish national registries contain information on patients seeking treatment for DUD, psychiatric disorders, and dispensed prescription drugs. In this nationwide study, we aimed to investigate the prescribing of BZDs in a population admitted for treatment of DUD. For patients with and without prior use of BZDs, we examined how their primary drug use and if psychiatric treatment prior to admission influenced BZD prescribing one year after admission. Finally, we assessed both the proportion of the different types of BZDs prescribed and the very long-term BZD prescription rates after admission into treatment.

**Methods**

**Study population**

This study included 33203 patients aged between 18 and 67 years old who were consecutively admitted for public outpatient treatment for DUD between January 1, 2000 and December 31, 2010 (Fig. 1).

**Data sources**

This study was based on data from the Danish Substance Abuse Treatment Register (DSATR) [26], the Danish National Prescription Database (DNPR) [27], and the Danish Psychiatric Central Research Register (PCRR) [28]. Data was obtained for the period of January 1, 1999 to December 31, 2011. All data sources were linked by use of the personal identification number, a unique identifier assigned to all Danish residents since 1968 [29].

The DSATR was used to identify patients in treatment for different DUDs. The register was established in 1996 and contains information on all patients receiving treatment in publically funded outpatient drug treatment facilities in Denmark. All treatment in these facilities is provided free of charge to the patient, as Denmark provides access to universal health care (including DUD treatment) for all residents. There are few privately funded drug treatment facilities, except for treatment of alcohol use disorders. Therefore practically all patients in treatment for DUDs are included in this study. The date of admission into treatment was registered. Patients are registered with one self-reported primary drug of abuse used upon admission into treatment, where patients are asked about “primary drug” in relation to treatment needs. Besides illicit non-prescription drugs, prescription
drugs such as methadone, buprenorphine, and BZDs could also be reported as their “primary drug” of abuse.

The DNPR contains information on all individual prescription drugs dispensed through pharmacies in Denmark since 1994 to patients outside of institutions such as hospitals and drug treatment facilities. Information about all prescriptions from ambulatory care, whether publicly reimbursed or not, is stored in the DNPR. Drugs are classified according to the Anatomical Therapeutic Chemical (ATC) classification [30]. The study used prescription data about BZDs, opioid analgesics, opioid maintenance medication (methadone, buprenorphine), and Z-hypnotics from the DNPR, which cover all patient prescriptions in Denmark. The data collected for this study included; patient unique identifying number (encrypted), gender, the date the medication was dispensed, and medication information [brand name, ATC-code, and defined daily dose (DDD)].

Benzodiazepines were defined by the ATC-code N05BA, N05CD, and N03AE01 in the ATC-classification system. Opioid analgesics were defined by the ATC-code N02A. Methadone and buprenorphine prescribed for opioid maintenance treatment were defined by the ATC-code N07BC02 and N07BC01/N07BC51, respectively. Z-hypnotics were defined by the ATC-code N05CF. Methadone and buprenorphine are used for both opioid maintenance treatment and pain treatment in Denmark. The present study included prescriptions of methadone and buprenorphine when these medications were prescribed for either indication. In this paper the terms ‘prescribed drug’ and ‘used drug’ are used interchangeably to describe dispensed drugs at pharmacies. For each prescription, the numbers of DDD dispensed were recorded. A DDD is defined as the assumed average maintenance dose per day for a medication used for its main indication in adults (Table 1) [30, 31].

Information about psychiatric diagnosis was obtained from the PCRR. The PCRR contains data on all psychiatric hospitalizations in Denmark since 1970, psychiatric ambulatory visits and emergency department contacts.
Table 1 ATC code and Defined Daily Dose (DDD) of prescribed benzodiazepines

| ATC code | 1 DDD (oral administration) | 584 DDD (oral administration) |
|----------|-----------------------------|--------------------------------|
| Alprazolam | N05BA12 | 1 mg | 584 mg |
| Bromazepam | N05BA08 | 10 mg | 5840 mg |
| Chlordiazepoxide | N05BA02 | 30 mg | 17520 mg |
| Clobazam | N05BA09 | 20 mg | 11680 mg |
| Clonazepam | N03AE01 | 8 mg | 4672 mg |
| Diazepam | N05BA01 | 10 mg | 5840 mg |
| Estazolam | N05CD04 | 3 mg | 1752 mg |
| Flunitrazepam | N05CD03 | 1 mg | 584 mg |
| Flurazepam | N05CD01 | 30 mg | 17520 mg |
| Lorazepam | N05BA06 | 2.5 mg | 1460 mg |
| Midazolam | N05CD08 | 15 mg | 8760 mg |
| Nitrazepam | N05CD02 | 5 mg | 2920 mg |
| Oxazepam | N05BA04 | 50 mg | 29200 mg |
| Triazolam | N05CD05 | 0.25 mg | 146 mg |

Abbreviations: ATC, Anatomical Therapeutic Chemical

*aIntake of 1 DDD daily of benzodiazepines in 1 year period results in a total intake of 365 DDD

since 1995. Discharge/contact diagnoses from the PCRR are coded according to ICD-10. A patient was only identified as having received psychiatric treatment if a diagnosis with the ICD-10 code F01-F99 was given during treatment. For certain analyses, these ICD-10 codes were further grouped into seven categories.

Analysis strategy
Study entry was set as the date of first admission into treatment for DUD during the study entry period, 2000–2010. We followed patients during the first year (365 days) after admission with respect to BZD prescription. Patients in the upper quartile received a yearly BZD dose of ≥584 DDD. The patients were categorized into two groups by amount prescribed during the first year after admission: (i) yearly dose <584 DDD (moderate-high dose) and (ii) yearly dose ≥584 DDD (very high dose). First, we compared characteristics at the time of admission between groups with and without a prescription for BZDs in moderate-high and very high doses. Further, for these groups we investigated the proportion of patients with a prescription for other potentially addictive drugs and psychiatric diagnoses. We assessed the proportion (%) with 95 % confidence intervals (CI) of different categories of psychiatric diagnoses that were given to patients with and without a prescription for BZDs in moderate-high and very high doses during the first year after admission.

Second, a prescription of BZDs during the year prior to admission into treatment may likely influence the prescription pattern after admission. Therefore we performed the following analyses in two different strata. In the first strata, we included patients with at least one prescription of BZDs in the year prior to admission (previous users). In the second strata, we included patients who had not received a BZD prescription in the year prior to admission, but who had at least one prescription of BZDs in the year after admission (new users). Variables potentially associated with prescription of BZDs in moderate-high and very high doses were estimated by multinomial logistic regression for both strata.

Third, we assessed the proportion of different types of BZDs in the moderate-high and the very high dose categories for both previous and new users. Finally, we investigated very long-term prescription of BZDs for previous and new users in 2000–2007 (N = 5374 and N = 2122, respectively). For this analysis, patients were consecutively excluded if they had died during the year of assessment (total; n = 510 and n = 120, respectively). A very long-term prescription of BZDs was defined as having had at least one prescription of BZDs in at least four consecutive years after the admission date, and included long-term sporadic use. We calculated the median and interquartile range (IQR 25 to 75 %) of DDDs of BZDs in the fourth year for each group.

Statistical analysis
All analyses were conducted using SPSS version 19.0 for Windows. To test for differences between groups, Chi-square analysis and t-test were used. Unadjusted and adjusted relative risk ratio (RRR and aRRR) with 95 % CI was estimated by multinomial regression analysis. In multinomial regression analysis, gender, age group at study entry date, primary drug use, and psychiatric diagnosis within 1 year prior to study entry were included in the model as independent variables. The level of significance was set to P < 0.05.
Ethics
The Danish Data Protection Agency has approved all procedures in relation to data collection from all used databases, and also storage of the data. The National Committee on Health Research Ethics in Denmark was informed about the study and determined that the study did not need to be reported to the Committee. All linkages were performed within Statistics Denmark, a governmental institution that collects and maintains electronic records for a broad spectrum of statistical and scientific purposes.

Results
A total of 33203 patients between the ages of 18 to 67 years were admitted for outpatient treatment for DUDs during January 1, 2000 until December 31, 2010. The mean age was 31 years (SD ± 11) at first admission, and 8177 (24.6 %) were female. During the first year after admission 8705 patients (26.2 %) were prescribed BZDs. The yearly mean dose prescribed was 438.1 DDD during the first year after admission, and the median was 175.0 DDD (interquartile range, 40.0 to 584.5). Of the patients with a BZD prescription, 3086 (35.5 %) were prescribed BZDs in a yearly dose higher than 365 DDD during the year after admission.

Table 2 compares characteristics in the groups with and without a BZD prescription in the different dosage categories at the time of admission. Age at admission was highest in the group with the highest amounts of prescribed BZDs (mean 41.0 years). The proportion of females was higher in groups with a BZD prescription compared to the group without a BZD prescription. Patients with opioids reported as their primary drug used were overrepresented in the group with the highest amounts of prescribed BZDs (Table 2). The proportion of patients with opioids as their primary drug used was 53.6 % in this group compared to 40.4 % in the group with the lowest amounts of BZDs, and 20.4 % in the group without a BZD prescription. Conversely, the patients with cannabis or central stimulating drugs reported as their primary drug used were overrepresented in the group without a prescription for BZDs. During the year prior to admission the proportion of patients receiving psychiatric treatment was lowest for the group without BZD prescription (16.9 %) and highest in the group with the lowest amounts of BZDs (27.3 %). Among patients without a BZD prescription during the

| No prescription of benzodiazepines 1 year after admission | Prescription of benzodiazepines 1 year after admission in moderate-high doses <584 DDD | Prescription of benzodiazepines 1 year after admission in very high doses ≥584 DDD | p value |
|----------------------------------------------------------|---------------------------------------------------------------------------------|---------------------------------------------------------------------------------|--------|
| N (%)                                                   | N (%)                                                                            | N (%)                                                                            |        |
| Number of individuals                                   | 24498                                                                            | 6528                                                                            | 2177   |
| Age in years at admission date, mean (SD)               | 29.2 ± 9.7                                                                      | 35.3 ± 10.7                                                                     | 41.0 ± 9.5 | <0.001 |
| Gender                                                  |                                                                                  |                                                                                  |        |
| Male                                                    | 18884                                                                           | 4630                                                                            | 1512   | 69.5   |
| Female                                                  | 5614                                                                            | 1898                                                                            | 665    | 30.5   |
| Primary drug use at admission                           |                                                                                  |                                                                                  | <0.001 |
| Cannabis                                                | 9212                                                                            | 1193                                                                            | 84     | 3.9    |
| Opioids                                                 | 5011                                                                            | 2639                                                                            | 1166   | 53.6   |
| Methadone or buprenorphine                              | 1236                                                                            | 955                                                                             | 594    | 27.3   |
| Heroin                                                  | 3454                                                                            | 1458                                                                            | 463    | 21.3   |
| Other opioids                                           | 321                                                                              | 226                                                                             | 109    | 5.0    |
| Benzodiazepines                                         | 213                                                                              | 207                                                                             | 83     | 3.8    |
| Central stimulating drugs\(^b\)                         | 3648                                                                            | 534                                                                             | 50     | 2.3    |
| Other illicit drugs/unknown                              | 6414                                                                            | 1955                                                                            | 794    | 36.5   |
| Psychiatric treatment received in 1 year prior to admission\(^c\) | 4148                                                                            | 1782                                                                            | 430    | 19.8   | <0.001 |
| Prescription of benzodiazepines 1 year prior to admission | 2464                                                                            | 4113                                                                            | 2026   | 93.1   | <0.001 |

Abbreviations: DUDs, drug use disorders; DDD, Defined Daily Dose
\(^a\) Intake of 1 DDD daily of benzodiazepines in a 1 year period results in a total intake of 365 DDD
\(^b\) Amphetamine, cocaine, and MDMA
\(^c\) Information obtained from the Danish Psychiatric Central Research Register
year after admission into treatment, 10.1 % were prescribed BZDs in the year prior to admission. However, in the groups with a prescription of BZDs after admission in lower and higher amounts, 63.0 % and 93.1 % respectively, were prescribed BZDs in the year prior to admission (Table 2).

During the year after admission, the proportion of patients with a prescription of potentially addictive drugs (opioid analgesics, opioid maintenance medication, and Z-hypnotics) was highest in the group with the highest amounts of BZDs and lowest in the group without a BZD prescription (Table 3).

During the year after admission, only the psychiatric diagnosis “mental and behavioral disorders due to psychoactive substance use” was more common in the groups with prescription of BZDs compared to the group without prescription of BZDs (Table 4).

From 2000 to 2010, the proportion of previous and new users with a BZD prescription during the first year after admission reduced continuously from 71.4 % and 18.1 % to 62.2 % and 5.9 %, respectively (data not shown).

With respect to factors associated with having a BZD prescription during the year after admission, the analyses were performed stratified according to the BZD prescription prior to admission (Tables 5 and 6). In both strata, no association after adjustment was observed between female gender and the prescription of very high amounts of BZDs. In the strata with new users of BZDs, females were more likely than males to be prescribed BZDs in moderate-high amounts (aRRR = 1.2, 95 % CI 1.1-1.3). Differences between strata in the association between age and BZD prescription in moderate-high and very high amounts were observed. In the strata with previous users of BZDs (Table 5), the RRR increased with increasing age in both dose categories (oldest age group: aRRR = 3.3, 2.7-3.9; aRRR = 7.8, 6.2-9.9). However in the strata with new users of BZDs, the RRR was increased only in older age groups among patients with prescription of BZDs in moderate-high amounts (aRRR = 3.3, 2.7-3.9).

Patients with opioids (methadone and buprenorphine; heroin) reported as their primary drug used were more likely to be prescribed BZDs in moderate-high and particularly very high doses, as compared to cannabis as their primary drug used in the strata of new BZD users (very high dose: aRRR (methadone and buprenorphine) = 45.7, 95 % CI 20.9-99.9; aRRR (heroin) = 17.1, 8.0-36.5) (Table 6). A similar but less strong association was observed in the strata of previous BZD users. Receiving psychiatric treatment prior to admission reduced the risk of being prescribed BZDs in very high doses in both strata (however, not significant for new users).

For both previous and new BZD users, the proportion of patients with prescription of more than one type of BZD was lowest for patients with prescription of BZDs in the lowest doses (29.2 %; 18.6 %) and highest for patients with prescription of BZDs in the highest doses (62.0 %; 66.9 %) (Table 7). Diazepam was the most commonly prescribed type of BZD to previous users (34.8 %), whilst oxazepam was the most common type prescribed to new users (28.6 %). However, among both of these groups with prescription of BZDs in only very high doses, nitrazepam was the most commonly prescribed type (53.7 %; 72.8 %).

A high proportion of patients with previous prescription of BZDs continued into very long-term use of prescribed BZDs after admission (4 years after admission: 62.6 %) (Fig. 2). Even in the group of patients without previous prescription of BZDs, 27.5 % continued into very long-term use. During the first year of prescription, the median and interquartile range of DDD was 343.9 (IQR 83.3 to 797.0); 50.0 (18.0 to 166.7) for previous and new users of BZDs, respectively. During the fourth year

**Table 3** Prescription of other addictive drugs and psychiatric treatment for patients in the first year after admission into treatment for DUDs

| Prescription of benzodiazepines 1 year after admission | N (%) | N (%) | N (%) | p value |
|-------------------------------------------------------|-------|-------|-------|---------|
| No prescription                                      | 24498 | 6528  | 2177  |         |
| Prescription of other drugs 1 year after admission    |       |       |       |         |
| Opioid analgesics                                     | 1677  | 6.9   | 1323  | 20.3    | 668     | 30.7    | <0.001  |
| Opioid maintenance medication (methadone, buprenorphine) | 2903  | 11.9  | 2271  | 34.8    | 1238    | 56.9    | <0.001  |
| Z-hypnotics                                           | 1489  | 6.1   | 1444  | 22.1    | 334     | 15.3    | <0.001  |
| Psychiatric treatment received in 1 year after admission | 3791  | 15.5  | 1825  | 28.0    | 431     | 19.8    | <0.001  |

Abbreviations: DUDs, drug use disorders; DDD, Defined Daily Dose

*Intake of 1 DDD daily of benzodiazepines in a 1 year period results in a total intake of 365 DDD

*Information obtained from the Danish Psychiatric Central Research Register
of prescription, the median and interquartile range of DDD was 405.0 (IQR 122.0 to 937.5); 118.8 (30.0 to 416.8) for previous and new users of BZDs, respectively.

Discussion
In this large nationwide study involving 33203 Danish patients admitted during an 11-year period to outpatient treatment for all types of DUDs, one out of four received at least one BZD prescription during the first year after admission. Of these, 29 % were new users of prescribed BZDs. Among patients with an opioid as their primary drug used, 43 % were prescribed BZDs during the first year after admission, which was three times higher than for patients with cannabis or central stimulating drugs as their primary drug used. Diazepam was the most commonly prescribed type of BZD. Collectively, the findings point toward a prescribing practice of BZDs that overall does not follow clinical guidelines, and indicate an inappropriate prescription of benzodiazepines in many cases more than treatment for psychiatric disorders.

Our findings are consistent with the results of other studies showing that users of OMT medication were prescribed higher doses of BZDs as compared to users of heroin [14].

Compared to the general population in the same age group and same time period in Denmark (one year prevalence 5-6 %) [23], the prevalence of BZD use was five times higher among patients with all types of DUD, and eight times higher among patients with opioids as their primary drug used. Although a decreasing trend in use of BZDs was observed in our study, the prevalence of BZD use in 2010 was approximately four times higher among patients with all types of DUD as compared to the general population. This excess BZD use among patients with DUD may therefore be of continued relevance after the study period.

In contrast to the general population, where female gender predicts BZD use, our study indicates that overall there was no association between gender and use of BZDs [34]. However, in consistency with the general population, use of BZDs was overall more common in older age groups compared with younger [25, 35].

Many of the patients admitted for DUD treatment require treatment for their harmful use of non-prescribed BZDs [36, 37]. The cessation of such non-prescribed BZDs is complex and often requires medical support, which can include the prescribing and tapering of BZDs [38]. In our study, more than one quarter of all users of BZDs were new users. Of these, one out of four

Table 4 Psychiatric diagnoses (ICD-10 code: F00-F99) given to patients in psychiatric treatment in the first year after admission into treatment for DUDs*

| Diagnosis                                                                 | No prescription of benzodiazepines 1 year after admission | Prescription of benzodiazepines 1 year after admission in moderate-high doses <584 DDD | Prescription of benzodiazepines 1 year after admission in very high doses ≥584 DDD |
|---------------------------------------------------------------------------|----------------------------------------------------------|---------------------------------------------------------------------------------------|----------------------------------------------------------------------------------|
| Mental and behavioural disorders due to psychoactive substance use (ICD-10 code: F10-F19) | 1821 (48.0 (46.4-49.6)) | 1127 (61.8 (59.5-64.0)) | 259 (60.1 (55.3-64.7)) |
| Schizophrenia and related disorders (ICD-10 code: F20-F29)                | 362 (9.5 (8.6-10.5)) | 226 (12.4 (10.9-14.0)) | 47 (10.9 (8.2-14.3)) |
| Mood disorders (ICD-10 code: F30-F39)                                     | 473 (12.5 (11.5-13.6)) | 217 (11.9 (10.5-13.5)) | 31 (7.2 (5.0-10.2)) |
| Neurotic, stress-related, and somatoform disorders (ICD-10 code: F40-F48) | 629 (16.6 (15.4-17.8)) | 296 (16.2 (14.6-18.0)) | 63 (14.6 (11.5-18.4)) |
| Disorders of adult personality and behaviour (ICD-10 code: F50-F59)       | 390 (10.3 (9.4-11.3)) | 194 (10.6 (9.3-12.2)) | 32 (7.4 (5.2-10.4)) |
| Behavioural and emotional disorders with onset in childhood (ICD-10 code: F90-F98) | 266 (7.0 (6.2-7.9)) | 53 (2.9 (2.2-3.8)) | 4 (0.9 (0.3-2.5)) |
| Other mental disorders (ICD-10 code: F00-F09, F50-F59, F70-F89, F99)*      | 253 (6.7 (5.9-7.5)) | 104 (5.7 (4.7-6.9)) | 26 (6.0 (4.1-8.8)) |
| Total*                                                                   | 4194                                                      | 2253                                                                                   | 462                                                                             |

Abbreviations: DUDs, drug use disorders; DDD, Defined Daily Dose

aInformation obtained from the Danish Psychiatric Central Research Register

bIntake of 1 DDD daily of benzodiazepines in a 1 year period results in a total intake of 365 DDD

F00-F09: Organic, including symptomatic, mental disorders; F50-F59: Behavioural syndromes associated with physiological disturbances and physical factors; F70-79: Mental retardation; F80-89: Disorders of psychological development; F99: Unspecified mental disorder

*It is possible for one patient to be given more than one type of psychiatric diagnosis
continued with a very long-term prescription. If a prescription of BZDs is initiated, it should normally not exceed four weeks, or a tapering down period should be agreed upon with the patient prior to treatment to avoid a long-term prescription [22]. For high-risk drug users and particularly opioid users, a short tapering down period with frequent medication pickup should be considered [39].

The amount of BZDs prescribed in this study was measured by use of DDD (Defined Daily Dose). The therapeutic amount of BZD for its main indication is defined as 1 DDD per day, equivalent to 365 DDD per year [30]. In our study, one-third were prescribed above 365 DDD per year, which indicates inappropriate use of BZD. Prescription of BZDs in high doses should in general be avoided, particularly for patients with DUD due to the high risk for abuse. Involvement of specialized psychiatric care might reduce the prescribing of BZDs in high doses by offering a psychiatric diagnostics that could inform an alternative and more effective therapeutic offer [40]. Our results support this as receiving psychiatric treatment prior to admission seemed to reduce the risk of being prescribed BZDs in very high doses.

Each type of BZD possess different effects, and their appeal to drug users differ accordingly [17]. In our study, diazepam was the most commonly prescribed type of BZD. This prescribing practice may be less than optimal, as diazepam has been reported as attractive among drug users given its fast onset and superior euphoriant effect compared to other types [17, 41, 42]. In addition to diazepam, other types of BZDs were prescribed, and one-third were prescribed more than one type of BZD. Use of more than one BZD at a time may indicate inappropriate use of BZDs [43]. This is supported by our findings as the majority of patients receiving BZDs in very high doses were prescribed more than one type of BZD.

The strengths of this study were that it covers all patients admitted to treatment for all types of DUD in a nationwide study. The unique personal identity number provides high quality linkages between the population-based registries on DUD treatment, prescriptions, and psychiatric treatment in Denmark. There were no missing outcome variables of prescribed medications due to complete registry linkage.

The limitations of this study were that medications dispensed at hospitals and other institutions, sometimes

| Table 5 | Relative risk ratio (RRR) from multinomial logistic regression of having a continued prescription of benzodiazepines according to different factors |
|---------|-------------------------------------------------------------------------------------|
|         | Prescription of benzodiazepines 1 year after admission in moderate-high doses <584 DDD<sup>a</sup> | Prescription of benzodiazepines 1 year after admission in very high doses ≥584 DDD<sup>a</sup> |
|         | Unadjusted RRR | Adjusted<sup>b</sup> RRR  (95 % CI) | p value | Unadjusted RRR | Adjusted<sup>b</sup> RRR  (95 % CI) | p value |
| Female  | 1.1 | 1.0 (0.9-1.2) | 0.310 | 1.2 | 1.0 (0.9-1.2) | 0.639 |
| Age group at admission date | | | |
| 18 – 27 years | 1.0 (referent) | 1.0 (referent) | 1.0 (referent) | 1.0 (referent) | 1.0 (referent) | 1.0 (referent) |
| 28 – 37 years | 1.8 | 1.7 (1.4-1.9) | <0.001 | 3.8 | 2.8 (2.3-3.5) | <0.001 |
| 38 – 47 years | 2.4 | 2.1 (1.8-2.4) | <0.001 | 7.6 | 4.9 (4.0-6.1) | <0.001 |
| 48 – 67 years | 3.7 | 3.3 (2.7-3.9) | <0.001 | 13.3 | 7.8 (6.2-9.9) | <0.001 |
| Primary drug use at admission | | | |
| Cannabis | 1.0 (referent) | 1.0 (referent) | 1.0 (referent) | 1.0 (referent) | 1.0 (referent) | 1.0 (referent) |
| Methadone or buprenorphine | 2.4 | 1.8 (1.5-2.2) | <0.001 | 15.2 | 8.3 (6.2-11.1) | <0.001 |
| Heroin | 1.5 | 1.3 (1.1-1.6) | 0.001 | 5.1 | 3.6 (2.7-4.8) | <0.001 |
| Other opioids | 2.0 | 1.5 (1.1-2.1) | 0.005 | 9.1 | 5.2 (3.6-7.7) | <0.001 |
| Benzodiazepines | 2.5 | 2.1 (1.5-2.8) | <0.001 | 9.4 | 6.9 (4.5-10.6) | <0.001 |
| Central stimulating drugs<sup>c</sup> | 0.9 | 0.9 (0.7-1.1) | 0.431 | 1.1 | 1.1 (0.7-1.7) | 0.633 |
| Other illicit drugs/unknown | 1.7 | 1.4 (1.2-1.6) | <0.001 | 7.6 | 4.6 (3.5-6.0) | <0.001 |
| Psychiatric treatment received in 1 year prior to admission<sup>d</sup> | 1.0 | 1.2 (1.0-1.3) | 0.006 | 0.6 | 0.6 (0.5-0.7) | <0.001 |

Group of previous users without prescription of benzodiazepines, n = 2464; group of previous users with prescription of benzodiazepines in moderate-high doses, n = 4113; group of previous users with prescription of benzodiazepines in very high doses, n = 2026.

Abbreviations: DDD, Defined Daily Dose; CI, confidence interval.

<sup>a</sup>Intake of 1 DDD daily of benzodiazepines in a 1 year period results in a total intake of 365 DDD.

<sup>b</sup>Adjusted for gender, age group at admission date, primary drug use at admission, and psychiatric treatment received in 1 year prior to admission.

<sup>c</sup>Amphetamine, cocaine, and MDMA.

<sup>d</sup>Information obtained from the Danish Psychiatric Central Research Register.
### Table 6: Relative risk ratio (RRR) from multinomial logistic regression of having a new prescription of benzodiazepines according to different factors

| Prescription of benzodiazepines 1 year after admission in moderate-high doses (<584 DDD) | Prescription of benzodiazepines 1 year after admission in very high doses (≥584 DDD) |
|-----------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------|
| Unadjusted RRR   | Adjusted<sup>b</sup> RRR   | p value | Unadjusted RRR   | Adjusted<sup>b</sup> RRR   | p value |
|------------------|---------------------------|---------|------------------|---------------------------|---------|
| Female           | 1.2                       | 1.2 (1.1-1.3) | <0.001 | 0.8                       | 0.8 (0.5-1.2) | 0.818 |
| Age group at admission date                                      |                                      |         | Age group at admission date                                      |                                      |         |
| 18 – 27 years     | 1.0 (referent)            | 1.0 (referent) |         | 1.0 (referent)            | 1.0 (referent) |         |
| 28 – 37 years     | 1.7                       | 1.4 (1.2-1.5) | <0.001 | 4.1                       | 1.9 (1.3-2.9) | 0.003 |
| 38 – 47 years     | 1.9                       | 1.3 (1.2-1.5) | <0.001 | 3.8                       | 1.2 (0.7-2.0) | 0.488 |
| 48 – 67 years     | 1.9                       | 1.3 (1.1-1.5) | 0.006  | 4.0                       | 1.1 (0.6-2.2) | 0.710 |
| Primary drug use at admission                                      |                                      |         | Primary drug use at admission                                      |                                      |         |
| Cannabis          | 1.0 (referent)            | 1.0 (referent) |         | 1.0 (referent)            | 1.0 (referent) |         |
| Methadone or buprenorphine                                       | 4.2                       | 3.8 (3.2-4.4) | <0.001 | 52.9                      | 45.7 (20.9-99.9) | <0.001 |
| Heroin            | 2.7                       | 2.5 (2.2-2.9) | <0.001 | 20.3                      | 17.1 (8.0-36.5) | <0.001 |
| Other opioids      | 2.8                       | 2.4 (1.7-3.3) | <0.001 | 22.5                      | 20.3 (6.5-63.7) | <0.001 |
| Benzodiazepines    | 4.2                       | 3.8 (2.7-5.4) | <0.001 | 14.2                      | 15.1 (3.2-71.7) | 0.001 |
| Central stimulating drugs<sup>c</sup>                             | 1.1                       | 1.0 (0.9-1.2) | 0.572 | 1.9                       | 1.9 (0.7-5.6) | 0.224 |
| Other illicit drugs/unknown                                      | 1.5                       | 1.4 (1.3-1.7) | <0.001 | 5.3                       | 5.2 (2.3-11.4) | <0.001 |
| Psychiatric treatment received in 1 year prior to admission<sup>d</sup> | 1.4                       | 1.5 (1.4-1.7) | <0.001 | 0.5                       | 0.7 (0.4-1.3) | 0.320 |

Group without prescription of benzodiazepines, n = 22034; group of new users with prescription of benzodiazepines in moderate-high doses, n = 2415; group of new users with prescription of benzodiazepines in very high doses, n = 151

Abbreviations: DDD, Defined Daily Dose; CI, confidence interval

<sup>a</sup>Intake of 1 DDD daily of benzodiazepines in a 1 year period results in a total intake of 365 DDD

<sup>b</sup>Adjusted for gender, age group at admission date, primary drug use at admission, and psychiatric treatment received in 1 year prior to admission

<sup>c</sup>Amphetamine, cocaine, and MDMA

<sup>d</sup>Information obtained from the Danish Psychiatric Central Research Register

### Table 7: Types of benzodiazepines prescribed to previous and new users in the first year after admission for treatment for DUDs

| Benzodiazepine type | Prescription of benzodiazepines to previous users in the first year after admission | Prescription of benzodiazepines to new users in the first year after admission |
|---------------------|-------------------------------------------------------------------------------------|--------------------------------------------------------------------------------|
|                     | Moderate-high doses (<584 DDD) N = 4113                                               | Very high doses (≥584 DDD) N = 2026                                           |
|                     | N | % | N | % | N | % | N | % |
| Alprazolam          | 398 | 9.7 | 287 | 14.2 | 200 | 8.2 | 32 | 21.2 |
| Bromazepam          | 303 | 7.4 | 450 | 22.2 | 101 | 4.2 | 30 | 19.9 |
| Chlordiazepoxide    | 692 | 16.8 | 189 | 9.3 | 624 | 25.8 | 20 | 13.2 |
| Clonazepam          | 739 | 18.0 | 252 | 12.4 | 305 | 12.6 | 14 | 9.3 |
| Diazepam            | 1224 | 29.8 | 914 | 45.1 | 484 | 20.0 | 50 | 33.1 |
| Flunitrazepam       | 82 | 2.0 | 201 | 9.9 | 46 | 1.9 | 18 | 11.9 |
| Nitrazepam          | 756 | 18.4 | 1087 | 53.7 | 393 | 16.3 | 110 | 72.8 |
| Oxazepam            | 1284 | 31.2 | 329 | 16.2 | 692 | 28.7 | 43 | 28.5 |
| Other               | 186 | 4.5 | 188 | 9.3 | 104 | 4.3 | 13 | 8.6 |
| Total<sup>b</sup>   | 5664 | 137.7 | 3897 | 192.3 | 2949 | 122.1 | 330 | 218.5 |
| Multiple            | 1202 | 29.2 | 1257 | 62.0 | 449 | 18.6 | 101 | 66.9 |

Abbreviations: DUDs, drug use disorders; DDD, Defined Daily Dose

<sup>a</sup>Intake of 1 DDD daily of benzodiazepines in a 1 year period results in a total intake of 365 DDD

<sup>b</sup>It is possible for one patient to be prescribed more than one type of benzodiazepine

---

Tjagvad et al. BMC Psychiatry (2016) 16:168
without individual prescriptions, are not registered at an individual level and hence are not included in this study. Benzodiazepines prescribed from drug treatment facilities to alleviate alcohol withdrawal symptoms are overall not included in the study, as BZDs prescribed with such an indication most often are dispensed from the treatment facility and not registered in the Danish National Prescription Database. Further, dispensed medications from pharmacies are not necessarily consumed by the recipients, and this study cannot account for persons who may have given away or sold their prescribed medications. If the type of BZD prescribed to one patient consecutively changed during a year it may have been registered as being prescription of multiple types of BZD. However, a high proportion of patients with prescription of multiple types of BZDs were receiving very high doses which could indicate use of more than one type at a time. Only OMT (opioid maintenance treatment) medication dispensed from a pharmacy was included in this study, as OMT medication dispensed from a drug treatment facility is not registered in the Danish National Prescription Database. Psychiatric diagnoses exclusively from general practitioners, drug treatment facilities, or somatic hospitals are not in registered the Danish Psychiatric Central Research Register and therefore not included in this study. Further, patients may have used a combination of drugs where choice of one primary drug use can be difficult and lead to misclassification.

**Conclusions**

The studied population in this nationwide sample included all patients with a DUD. In that view, regardless of the primary drug used, patients had too high prescription rates of BZDs, and this particularly applied to patients with an opioid use disorder. Our findings therefore have relevance for all physicians involved in DUD treatment.

Given that BZDs only have a very narrow indication as psychiatric treatment for this patient group, the current treatment as presented in this study seems less than optimal. This is underlined by the finding that admitting into treatment for DUDs with prescribed BZDs did not seem to increase specialized psychiatric care involvement. No difference regarding the prevalence of anxiety disorders have been reported among patients with different types of DUDs [12]. Still, the proportion of BZD users was three times higher among patients treated for opioid use when compared to patients treated for use of cannabis or central stimulants drugs. Opioids combined with BZDs are known to induce a greater level of euphoria, as opposed to cannabis and central stimulating drugs. Further, inappropriate prescription patterns of BZD were identified in this study with prescription of multiple and non-optimal types, high doses, very long-term prescription, and co-prescription of other potentially addictive drugs.

Overall, BZDs were prescribed to DUD patients in a fashion that in many cases indicated inappropriate prescribing to patients more than treatment for psychiatric disorders. This finding might reflect a liberal prescribing practice among physicians at drug treatment facilities in Denmark, which has previously been described regarding other addictive medications [44, 45]. Further, it emphasizes the potential risk of harm when BZD prescribing practices do not follow clinical guidelines. Our results reinforce the need for health systems to promote the use of prescription drug monitoring programs to identify inappropriate BZD prescribing patterns among patients, and help physicians link such patients to more appropriate care. Patients with patterns of inappropriate BZD use deserve medical support while tapering off their BZD dependence. DUD patients with comorbid psychiatric disorders in need of long-term BZD prescription are likely a minority, and co-management of specialized psychiatric care should be considered part of an appropriate BZD treatment for this patient group. For the remainder of the patients, physicians would likely benefit their patients if
BZDs are avoided rather than prescribed; however to hold the restrictive role is more of a challenge than to be a liberal prescriber.

Abbreviations
DUD, drug use disorders; BZDs, benzodiazepines; DSATR, Danish Substance Abuse Treatment Register; DNPR, Danish National Prescription Database; PCRR, Danish Psychiatric Central Research Register; ATC, Anatomical Therapeutic Chemical; CI, confidence intervals; DDD, defined daily dose; IQR, interquartile range; RR, relative risk ratio; aRRR, adjusted relative risk ratio; OMT, opioid maintenance treatment

Acknowledgements
None.

Funding
This study was financially supported by The Danish Ministry of Health. The funding source had no role in: the study design; the collection, analysis, and interpretation of data; the writing of the manuscript; or the decision to submit the paper for publication.

Availability of data and materials
According to the Danish Legislation, this type of sensitive and confidential data can only be made available for researchers who have obtained permission from data authorities. For further information, please contact MD Christian Tjagvad, Norwegian Centre for Addiction Research.

Authors’ contributions
CT helped design the study, was responsible for the data collection, and wrote the protocol, data interpretation. MH participated in conducting the statistical analyses and in data interpretation. TC helped design the study, wrote the first draft of the manuscript. SS helped design the study, participated in conducting the statistical analyses and in data interpretation. All authors contributed to and have approved the final manuscript.

Competing interests
The authors declare that they have no competing interests.

Consent for publication
Not applicable.

Ethics approval and consent to participate
This research was based on data collected for administrative and monitoring purposes. According to Danish law, such studies are not subject to evaluation by the regional ethics committees. As this study was based on register data, the participants were not contacted and informed consent was not obtained. To the knowledge of the authors, no burden or risk was imposed on the patients included in this study as a result of the research conducted and no individuals can be identified from the data presented.

Author details
1Norwegian Centre for Addiction Research [SERAf], University of Oslo, Kirkeveien 166, Bygg 45, 0407 Oslo, Norway. 2Department of Pharmacoepidemiology, Norwegian Institute of Public Health, Oslo, Norway.

Received: 8 December 2015 Accepted: 20 May 2016
Published online: 27 May 2016

References
1. Degenhardt L, Whiteford HA, Ferrari AJ, Baxter AJ, Charlson FJ, Hall WD, et al. Global burden of disease attributable to illicit drug use and dependence: findings from the Global Burden of Disease Study 2010. Lancet. 2013;382(9906):1564–74.

2. Denis C, Lavie E, Fatseas M, Auriacombe M. Psychotherapeutic interventions for cannabis abuse and/or dependence in outpatient settings. Cochrane Database Syst Rev. 2006;3:CD005336.

3. Knapp WP, Soares BG, Farrell M, Lima MS. Psychosocial interventions for cocaine and psychostimulant amphetamines related disorders. Cochrane Database Syst Rev. 2007;3:CD003023.

4. Gibson A, Degenhardt L, Mattick RP, Ali R, White J, O’Brien S. Exposure to opioid maintenance treatment reduces long-term mortality. Addiction (Abingdon, England). 2008;103(3):462–8.

5. Mattick RP, Breen C, Kimber J, Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev. 2014;2:CD002207.

6. The Danish Health and Medicines Authority. The drug situation in Denmark 2014 Copenhagen: The Danish Health and Medicines Authority, 2014 [Available at: http://sundhedsstyrelsen.dk/en/news/2014/the-drug-situation-in-denmark]

7. Ashton H. Guidelines for the rational use of benzodiazepines. When and what to use. Drugs. 1994;48(1):25–40.

8. Brunette MF, Nooordsy DL, Xie H, Drake RE. Benzodiazepine use and abuse among patients with severe mental illness and co-occurring substance use disorders. Psychiatric services (Washington, DC). 2003;54(10):1395–401.

9. Bramness JG, Korror H. Benzodiazepine prescription for patients in opioid maintenance treatment in Norway. Drug Alcohol Depend. 2007;90(2–3):203–9.

10. Grant BF, Stinson FS, Dawson DA, Chou SP, Dufour MC, Compton W, et al. Prevalence and co-occurrence of substance use disorders and independent mood and anxiety disorders: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Arch Gen Psychiatry. 2004;61(8):807–16.

11. Clark RE, Xie H, Brunette MF. Benzodiazepine prescription practices and substance abuse in persons with severe mental illness. J Clin Psychiatry. 2004;65(2):151–5.

12. Chen KW, Banducci AN, Guller L, Macatee RJ, Lavelle A, Daughters SB, et al. An examination of psychiatric comorbidities as a function of gender and substance type within an inpatient substance use treatment program. Drug Alcohol Depend. 2011;118(2–3):92–9.

13. Griffiths RR, Weerts EM. Benzodiazepine self-administration in humans and laboratory animals—implications for problems of long-term use and abuse. Psychopharmacology (Berl). 1997;134(1):1–37.

14. Backmund M, Meyer K, Henkel C, Soyka M, Reimer J, Schütz CG. Co-consumption of benzodiazepines in heroin users, methadone-substituted and codeine-substituted patients. J Addict Dis. 2005;24(4):17–29.

15. Taylor S, McCracken CF, Wilson KC, Copeland JR. Extent and appropriateness of benzodiazepine use. Results from an elderly urban community. Br J Psychiatry. 2004;185(3):221–2.

16. Buffett-Jenrot SE, Stewart SH. Cognitive and sedative effects of benzodiazepine use. Curr Pharm Des. 2002;8(4):15–58.

17. O’Brien CP. Benzodiazepine use, abuse, and dependence. J Clin Psychiatry. 2005;66 Suppl 2:22–8.

18. Voshaar RC, Couvee JE, van Balkom AJ, Mulder PG, Zitman FG. Strategies for discontinuing long-term benzodiazepine use: meta-analysis. Br J Psychiatry J Ment Sci. 2006;182(3):213–20.

19. Malcolm R, Brady KT, Johnston AL, Cunningham M. Types of benzodiazepines abused by chemically dependent inpatients. J Psychoactive Drugs. 1993;25(4):315–9.

20. Pradel V, Delga C, Rouby F, Micallef J, Lapeyre-Mestre M. Assessment of ‘doctor shopping’ as an indicator. CNS Drugs. 2010;24(7):611–23.

21. Nicolai RM, Brady KT, Johnston AL, Cunningham M. Types of benzodiazepine use. Curr Pharm Des. 2002;8(1):45–51.

22. The Danish Ministry of Health. Vejledning om ordination af BZDs: behandlingen af stofmisbrug. Copenhagen; 2015 [Available at: http://www.stofmisbrugsdatabasen.dk].

23. Sundhedsanalyser og Lægemiddelstatistik. Medstat.dk: Sundhedsdatastyrelsen; 2016 Available at: http://medstat.dk

24. Holm E, Fosbol E, Pedersen H, Jensen TB, Nielsen M, Weeke P, et al. Benzodiazepine use in Denmark 1997–2008. European Geriatric Medicine. 2012;3(5):299–303.

25. The National Board of Health and Welfare. Stofmisbrugsdatabasen (Register of Individuals in Treatment for Substance Use Disorders): The National Board of Health and Welfare, Copenhagen; 2015 [Available at: http://www.stofmisbrugsdatabasen.dk].

26. Kildemoes HW, Sorensen HT, Hallas J. The Danish National Prescription Registry. Scand J Public Health. 2011;39(7 Suppl):38–41.
28. Mors O, Perto GP, Mortensen PB. The Danish Psychiatric Central Research Register. Scand J Public Health. 2011;39(7 Suppl):54–7.
29. Pedersen CB. The Danish Civil Registration System. Scand J Public Health. 2011;39(7 Suppl):22–5.
30. WHO Collaborating Centre for Drug Statistics Methodology. Guidelines for ATC Classification and DDD Assignment. Oslo, Norway: Norwegian Institute of Public Health, 2007.
31. Hausken AM, Furu K, Skurtveit S, Engeland A, Bramness JG. Starting insomnia treatment: the use of benzodiazepines versus z-hypnotics. A prescription database study of predictors. Eur J Clin Pharmacol. 2009;65(3):295–301.
32. Wei HT, Chen MH, Wong WW, Chou YH, Liou YJ, Su TP, et al. Benzodiazepines and Z-drug use among HIV-infected patients in Taiwan: a 13-year nationwide cohort study. BioMed Res Int. 2015;2015:465726.
33. Gronnerud L, Mahic M, Bramness JG. Bruk av benzodiazepiner og z-hypnotika blant pasienter i LAR. Norsk Farmaceutisk Tidsskrift. 2014;1053–7.
34. Naja WJ, Pelissolo A, Haddad RS, Baddoura R, Baddoura C. A general population survey on patterns of benzodiazepine use and dependence in Lebanon. Acta Psychiatr Scand. 2000;102(6):429–31.
35. Isacson D. Long-term benzodiazepine use: factors of importance and the development of individual use patterns over time—a 13-year follow-up in a Swedish community. Soc Sci Med. 1997;44(12):1871–80.
36. Chen KW, Berger CC, Forde DP, D’Adamo C, Weintraub E, Gandhi D. Benzodiazepine use and misuse among patients in a methadone program. BMC Psychiatry. 2011;11:90.
37. Gelkopf M, Bleich A, Hayward R, Bodner G, Adelson M. Characteristics of benzodiazepine abuse in methadone maintenance treatment patients: a 1 year prospective study in an Israeli clinic. Drug Alcohol Depend. 1999;55(1-2):63–8.
38. Ashton H. The diagnosis and management of benzodiazepine dependence. Curr Opin Psychiatry. 2005;18(3):249–55.
39. European Monitoring Centre for Drug and Drug Addiction (EMCDDA). The misuse of benzodiazepines among high-risk opioid users in Europe Lisbon. Portugal: EMCDDA, 2015.
40. Vogel M, Knopfli B, Schmid O, Prica M, Strasser J, Prieto L, et al. Treatment or “high”: benzodiazepine use in patients on injectable heroin or oral opioids. Addict Behav. 2013;38(10):2477–84.
41. Oztack MH, Friedman L, Dessain E, Bird M, Beake B, McEachern J, et al. Comparative study of the abuse liability of alprazolam, lorazepam, diazepam, methaqualone, and placebo. Int J Addict. 1988;23(5):449–67.
42. Griffiths RR, Johnson MW. Relative abuse liability of hypnotic drugs: a conceptual framework and algorithm for differentiating among compounds. J Clin Psychiatry. 2005;66 Suppl 9:31–41.
43. Manthey L, van Veen T, Giltay EJ, Stoop JE, Neven AK, Penninx BW, et al. Correlates of (inappropriate) benzodiazepine use: the Netherlands Study of Depression and Anxiety (NESDA). Br J Clin Pharmacol. 2011;71(2):263–72.
44. Skrentny A, Rosenqvist P. Shifting focus in substitution treatment in the Nordic countries. Nordic Studies on Alcohol and Drugs. 2010;27(6):581–97.
45. Frank VA, Bjerge B, Houborg E. Shifts in opioid substitution treatment policy in Denmark from 2000–2011. Subst Use Misuse. 2013;48(11):997–1009.